公开(公告)号：US20240174601A1

公开(公告)日：2024-05-30

申请号：US18282281

申请日：2022-03-08

申请人： BASF SE

发明人： Yang YANG ,  Xiao Yu SUN ,  Dong LIANG ,  Stefan BOKERN ,  Johannes BARTH ,  Peter DEGLMANN

IPC分类号： C07C263/18 ,  C07C265/12 ,  C07D207/12 ,  C07D233/02 ,  C07D275/03

CPC分类号： C07C263/18 ,  C07C265/12 ,  C07D207/12 ,  C07D233/02 ,  C07D275/03

摘要： This disclosure relates to a composition comprising (a) 4,4′-methylene diphenyl diisocyanate (4,4′-MDI), and (b) at least one heterocyclic compound comprising as ring moiety at least one structure of formula (I) as defined in the description. The heterocyclic compound can suppress the formation of 4,4′-MDI dimer and thus prevent the formation of insoluble solids and extend the shelf life of 4,4′-MDI.

公开(公告)号：US20230373947A1

公开(公告)日：2023-11-23

申请号：US18229277

申请日：2023-08-02

申请人： MITSUI CHEMICALS, INC.

发明人： Kei Yoshida ,  Takeo Wakita ,  Hiroyuki Katsuta ,  Akiyoshi Kai ,  Yutaka Chiba ,  Kiyoshi Takahashi ,  Hiroko Kato ,  Nobuyuki Kawahara ,  Michikazu Nomura ,  Hidenori Daido ,  Junji Maki ,  Shinichi Banba

IPC分类号： C07D333/38 ,  A01N37/44 ,  A01N43/08 ,  A01N43/10 ,  A01N43/12 ,  A01N43/16 ,  A01N43/30 ,  A01N43/42 ,  A01N43/54 ,  A01N43/56 ,  A01N43/58 ,  A01N43/78 ,  A01N43/80 ,  C07C237/42 ,  C07C317/40 ,  C07C323/42 ,  C07C327/48 ,  C07D207/416 ,  C07D213/64 ,  C07D213/73 ,  C07D213/81 ,  C07D213/82 ,  C07D213/89 ,  C07D215/52 ,  C07D231/14 ,  C07D231/16 ,  C07D239/30 ,  C07D241/24 ,  C07D263/34 ,  C07D275/03 ,  C07D277/56 ,  C07D307/24 ,  C07D307/68 ,  C07D307/84 ,  C07D309/08 ,  C07D309/28 ,  C07D317/62 ,  C07D333/68 ,  A01N43/40 ,  A01N37/22 ,  A01N43/60 ,  C07C237/48 ,  C07D207/34 ,  C07D239/28 ,  C07D261/18 ,  C07D307/85 ,  C07D317/46

CPC分类号： C07D333/38 ,  A01N37/44 ,  A01N43/08 ,  A01N43/10 ,  A01N43/12 ,  A01N43/16 ,  A01N43/30 ,  A01N43/42 ,  A01N43/54 ,  A01N43/56 ,  A01N43/58 ,  A01N43/78 ,  A01N43/80 ,  C07C237/42 ,  C07C317/40 ,  C07C323/42 ,  C07C327/48 ,  C07D207/416 ,  C07D213/64 ,  C07D213/73 ,  C07D213/81 ,  C07D213/82 ,  C07D213/89 ,  C07D215/52 ,  C07D231/14 ,  C07D231/16 ,  C07D239/30 ,  C07D241/24 ,  C07D263/34 ,  C07D275/03 ,  C07D277/56 ,  C07D307/24 ,  C07D307/68 ,  C07D307/84 ,  C07D309/08 ,  C07D309/28 ,  C07D317/62 ,  C07D333/68 ,  A01N43/40 ,  A01N37/22 ,  A01N43/60 ,  C07C237/48 ,  C07D207/34 ,  C07D239/28 ,  C07D261/18 ,  C07D307/85 ,  C07D317/46

摘要： A compound represented by Formula (1):




The compound can be used as insecticides.

公开(公告)号：US11821032B2

公开(公告)日：2023-11-21

申请号：US16999329

申请日：2020-08-21

申请人： IsoPlexis Corporation

发明人： Luisa Andruzzi ,  Jimmy Adediran ,  Timothy Pelletier ,  Austin Ricker ,  Angela DeLucia ,  Ben McNally ,  Dona Hevroni ,  Mong Sano Marma ,  John Andrew Sheridan

IPC分类号： C12P19/34 ,  C12Q1/6869 ,  C12Q1/6876 ,  C12Q1/6806 ,  C07D275/03

CPC分类号： C12Q1/6869 ,  C12Q1/6806 ,  C12Q1/6876 ,  C07D275/03 ,  C12Q2525/113 ,  C12Q2525/186 ,  C12Q2600/16 ,  C12Q1/6869 ,  C12Q2525/113 ,  C12Q2525/117 ,  C12Q2525/186

摘要： The present invention provides methods, compositions, mixtures and kits utilizing 5-Chloro-2-methyl-4-isothiazolin-3-one in sequencing reactions, and in particular, sequencing reactions where deoxynucleoside triphosphates comprising a 3′-O position capped by a disulfide-based 3′-terminator group are used. In one embodiment, the deoxynucleoside triphosphates comprise a 3′-O position capped by a group comprising methylenedisulfide as a cleavable protecting group and a detectable label reversibly connected to the nucleobase of said deoxynucleoside. In addition, thiol-containing compounds and scavengers of thio-containing compounds are described. Such compounds provide new possibilities for future sequencing technologies, including but not limited to Sequencing by Synthesis.

公开(公告)号：US20230339851A1

公开(公告)日：2023-10-26

申请号：US18186265

申请日：2023-03-20

申请人： CHEMOCENTRYX, INC.

发明人： Hiufung CHU ,  Pingchen FAN ,  Yandong LI ,  Viengkham MALATHONG ,  Jay POWERS ,  Hiroko TANAKA ,  Yibin ZENG ,  Penglie ZHANG

IPC分类号： C07D231/14 ,  C07D261/18 ,  C07D317/60 ,  C07D237/24 ,  C07D309/10 ,  C07D275/03 ,  C07D319/12 ,  C07D307/24 ,  C07D207/16 ,  C07D309/06 ,  C07D493/08 ,  C07D295/195 ,  C07D239/28 ,  C07D307/16 ,  C07D265/30 ,  C07D309/28 ,  C07D309/08 ,  C07D211/60 ,  C07D207/22 ,  C07D233/90 ,  C07D317/66 ,  C07D211/62 ,  C07D335/02 ,  C07C311/44 ,  C07D307/68 ,  C07D213/81 ,  C07D471/08

CPC分类号： C07C311/44 ,  C07D207/16 ,  C07D207/22 ,  C07D211/60 ,  C07D211/62 ,  C07D213/81 ,  C07D231/14 ,  C07D233/90 ,  C07D237/24 ,  C07D239/28 ,  C07D261/18 ,  C07D265/30 ,  C07D275/03 ,  C07D295/195 ,  C07D307/16 ,  C07D307/24 ,  C07D307/68 ,  C07D309/06 ,  C07D309/08 ,  C07D309/10 ,  C07D309/28 ,  C07D317/60 ,  C07D317/66 ,  C07D319/12 ,  C07D335/02 ,  C07D471/08 ,  C07D493/08 ,  C07C2601/02 ,  C07C2601/04 ,  C07C2601/08 ,  C07C2601/14 ,  C07C2601/16 ,  C07C2601/18 ,  C07C2602/08 ,  C07C2602/18 ,  C07C2602/42

摘要： Provided are sulfonamide compounds having formula (I):





or a pharmaceutically acceptable salt thereof, wherein R, R1, R2, R3, R4 and the subscripts n and m have the meanings provided in the specification. The compounds are useful for treating diseases and conditions associated with CXCR6 activity.

公开(公告)号：US20190241578A1

公开(公告)日：2019-08-08

申请号：US16389355

申请日：2019-04-19

申请人： DREXEL UNIVERSITY

发明人： Sandhya KORTAGERE ,  Ole MORTENSEN ,  Andreia C. K. MORTENSEN ,  Joseph M. SALVINO

IPC分类号： C07D487/04 ,  A61K31/4709 ,  A61K31/53 ,  C07D275/03 ,  C07D401/04 ,  C07D413/14 ,  C07D417/12 ,  A61K31/427 ,  A61K31/5365 ,  A61K31/47 ,  A61K31/4406 ,  A61K31/425 ,  A61K31/42 ,  A61K31/4196 ,  A61K31/4184 ,  A61K31/381 ,  A61K31/341 ,  A61K31/4439 ,  A61K45/06 ,  A61K31/635 ,  C07D261/14

CPC分类号： C07D487/04 ,  A61K31/341 ,  A61K31/381 ,  A61K31/4184 ,  A61K31/4196 ,  A61K31/42 ,  A61K31/425 ,  A61K31/427 ,  A61K31/4406 ,  A61K31/4439 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/53 ,  A61K31/5365 ,  A61K31/635 ,  A61K45/06 ,  C07D261/14 ,  C07D275/03 ,  C07D401/04 ,  C07D413/14 ,  C07D417/12 ,  A61K2300/00

摘要： The present invention provides compounds useful for treating or preventing a brain-related disease or disorder. The present invention further provides a method of treating or preventing a brain-related disease or disorder in a patient, comprising administering to the patient a pharmaceutical composition comprising at least one compound of the invention. The present invention further provides a method of modulating the activity of a monoamine transporter.

公开(公告)号：US20190127776A1

公开(公告)日：2019-05-02

申请号：US16224006

申请日：2018-12-18

申请人： University of Cincinnati ,  Government of the United States as Represented by the Secretary of the Air Force

发明人： Daniel J. Hassett ,  Thomas J. Lamkin ,  Warunya Panmanee ,  Deborah E. Taylor ,  Chloe J.A. Shea

IPC分类号： C12Q1/18 ,  C07D405/14 ,  A61K31/175 ,  C07D471/04 ,  C07C243/28 ,  C07C311/21 ,  C07D209/08 ,  C07D215/52 ,  C07D215/56 ,  C07D231/20 ,  C07D235/18 ,  C07D271/12 ,  C07D275/03 ,  C07D307/92 ,  C07D401/04 ,  C07D405/04 ,  C07D413/04 ,  A01N37/10 ,  A01N37/28 ,  A01N41/06 ,  A01N43/12 ,  A01N43/38 ,  A01N43/42 ,  A01N43/44 ,  A01N43/52 ,  A01N43/54 ,  A01N43/56 ,  A01N43/80 ,  A01N43/82 ,  A01N43/90 ,  A01N47/38 ,  C07C69/738 ,  A61K31/519 ,  A61K31/506 ,  A61K31/496 ,  A61K31/4709 ,  A61K31/4545 ,  A61K31/435 ,  A61K31/425 ,  A61K31/4245 ,  A61K31/4184 ,  A61K31/4155 ,  A61K31/404 ,  A61K31/343 ,  A61K31/216 ,  A61K31/18 ,  C07D491/052

CPC分类号： C12Q1/18 ,  A01N37/10 ,  A01N37/28 ,  A01N41/06 ,  A01N43/12 ,  A01N43/38 ,  A01N43/42 ,  A01N43/44 ,  A01N43/52 ,  A01N43/54 ,  A01N43/56 ,  A01N43/80 ,  A01N43/82 ,  A01N43/90 ,  A01N47/38 ,  A61K31/175 ,  A61K31/18 ,  A61K31/216 ,  A61K31/343 ,  A61K31/404 ,  A61K31/4155 ,  A61K31/4184 ,  A61K31/4245 ,  A61K31/425 ,  A61K31/435 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/506 ,  A61K31/519 ,  C07C69/738 ,  C07C243/28 ,  C07C311/21 ,  C07D209/08 ,  C07D215/52 ,  C07D215/56 ,  C07D231/20 ,  C07D235/18 ,  C07D271/12 ,  C07D275/03 ,  C07D307/92 ,  C07D401/04 ,  C07D405/04 ,  C07D405/14 ,  C07D413/04 ,  C07D471/04 ,  C07D491/052

摘要： A high through-put screening method for identifying agents effective for inhibiting biofilm formation and/or killing established biofilm are disclosed. The method includes three tiers, and each tier includes three specific biological process assays. The tier levels are a primary screen, a confirmation screen, and a dose-response screen, and the biological process assays include assays for total bacterial growth, bacterial metabolic activity, and biofilm formation. The series of assays may be run once or more than once at each tier. A library of compounds is subject to tier A and only compounds meeting a primary parameter advance to tier B, and only tier B compounds meeting a confirmation parameter advance to tier C, and only tier C compounds meeting a dose-response parameter are identified as putative agents effective for inhibiting and/or eradicating a biofilm, further wherein the assays are conducted for each compound subject to the respective tier. The method is effective and validated for identifying agents which inhibit and/or kill Staphylococcus epidermidis, Pseudomonas aeruginosa, and Acinetobacter baumannii biofilms. Agents identified according to the high through-put screen and validated in follow-up experiments as effective for inhibiting and/or killing bacterial biofilms are also disclosed.

公开(公告)号：US20180358655A1

公开(公告)日：2018-12-13

申请号：US15562348

申请日：2016-03-29

申请人： SUMITOMO SEIKA CHEMICALS CO., LTD.

发明人： Yuki KONO ,  Yasuyuki TAKAI ,  Koji FUJITA ,  Noriko YAMAMOTO

IPC分类号： H01M10/0567 ,  H01G11/22 ,  H01G11/62 ,  H01G11/60 ,  H01M10/0525 ,  H01M10/0568 ,  H01M10/0569 ,  C07D207/48 ,  C07D209/48 ,  C07D231/12 ,  C07D275/03 ,  C07D275/06 ,  C07D285/01

CPC分类号： H01M10/0567 ,  C07D207/48 ,  C07D209/48 ,  C07D231/12 ,  C07D275/03 ,  C07D275/06 ,  C07D285/01 ,  H01G11/22 ,  H01G11/60 ,  H01G11/62 ,  H01G11/64 ,  H01M10/052 ,  H01M10/0525 ,  H01M10/0568 ,  H01M10/0569 ,  H01M2300/0037 ,  Y02E60/13

摘要： An additive for a non-aqueous electrolyte solution including a compound represented by the following formula (A1) or (A2). In the formula, Xa represents a group that forms a cyclic group together with a nitrogen atom, Za1 and Za2, Za1 and Za2 each independently represent a sulfonyl or carbonyl group, Ra1 represents an optionally substituted alkylene group of 1 to 4 carbon atoms, an alkenylene group of 3 or 4 carbon atoms or an alkynylene group of 3 or 4 carbon atoms, Ra2 represents a hydrogen atom, a halogen atom or an optionally substituted alkyl group of 1 to 4 carbon atoms, Ra3 represents oxygen or an optionally substituted alkylene group of 1 to 4 carbon atoms, alkenylene group of 3 or 4 carbon atoms or alkynylene group of 3 or 4 carbon atoms.

公开(公告)号：US20180118696A1

公开(公告)日：2018-05-03

申请号：US15696713

申请日：2017-09-06

申请人： THERAVANCE BIOPHARMA R&D IP, LLC

发明人： Melissa Fleury ,  Anne-Marie Beausoleil ,  Adam D. Hughes ,  Daniel D. Long ,  Donna A.A. Wilton

IPC分类号： C07D249/04 ,  C07D249/10 ,  C07D231/14 ,  C07D261/18 ,  C07D263/34 ,  C07D263/38 ,  C07D271/07 ,  C07D239/28 ,  C07D231/20 ,  C07D275/03 ,  C07D471/04 ,  C07D403/12 ,  C07D213/81

CPC分类号： C07D249/04 ,  A61K31/415 ,  A61K31/4192 ,  A61K31/4196 ,  A61K31/42 ,  A61K31/421 ,  A61K31/4245 ,  A61K31/425 ,  A61K31/437 ,  A61K31/44 ,  A61K31/4985 ,  A61K31/505 ,  A61K45/06 ,  A61P9/04 ,  A61P9/12 ,  A61P13/12 ,  C07C229/34 ,  C07C271/22 ,  C07D213/81 ,  C07D231/14 ,  C07D231/18 ,  C07D231/20 ,  C07D233/70 ,  C07D233/90 ,  C07D235/08 ,  C07D237/14 ,  C07D239/28 ,  C07D239/34 ,  C07D249/10 ,  C07D249/12 ,  C07D249/18 ,  C07D261/12 ,  C07D261/18 ,  C07D263/18 ,  C07D263/34 ,  C07D263/38 ,  C07D271/07 ,  C07D275/03 ,  C07D295/10 ,  C07D309/40 ,  C07D319/06 ,  C07D401/04 ,  C07D403/04 ,  C07D403/06 ,  C07D403/12 ,  C07D405/12 ,  C07D405/14 ,  C07D471/04

摘要： In one aspect, the invention relates to compounds having the formula I: where R1-R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.

公开(公告)号：US20180003702A1

公开(公告)日：2018-01-04

申请号：US15244135

申请日：2016-08-23

申请人： SENOMYX, INC.

发明人： Xiaodong LI ,  Lena LUUKKONEN ,  Hong XU

IPC分类号： G01N33/543 ,  A23L27/00 ,  A23L27/20 ,  G01N33/566 ,  G01N33/50 ,  C07F9/655 ,  C07D405/12 ,  C07D317/68 ,  C07D307/84 ,  C07C275/34 ,  C07C275/30 ,  C07C235/54 ,  C07C233/65 ,  A61K47/24 ,  A61K47/22 ,  A61K8/55 ,  A61K8/49 ,  A23L2/56 ,  G01N33/74

CPC分类号： G01N33/543 ,  A23L2/56 ,  A23L27/202 ,  A23L27/203 ,  A23L27/2054 ,  A23L27/88 ,  A23V2002/00 ,  A61K8/4973 ,  A61K8/55 ,  A61K47/22 ,  A61K47/24 ,  C07C233/65 ,  C07C235/54 ,  C07C275/30 ,  C07C275/34 ,  C07D209/08 ,  C07D209/42 ,  C07D213/40 ,  C07D213/81 ,  C07D213/85 ,  C07D215/48 ,  C07D217/06 ,  C07D231/14 ,  C07D261/18 ,  C07D263/56 ,  C07D271/12 ,  C07D275/03 ,  C07D277/64 ,  C07D285/135 ,  C07D307/52 ,  C07D307/68 ,  C07D307/79 ,  C07D307/82 ,  C07D307/84 ,  C07D317/68 ,  C07D333/24 ,  C07D333/38 ,  C07D401/04 ,  C07D405/12 ,  C07D409/12 ,  C07D417/12 ,  C07F9/65517 ,  G01N33/5041 ,  G01N33/566 ,  G01N33/74 ,  G01N2333/726

摘要： The invention relates to compounds that specifically bind a T1R1/T1R3 or T1R2/T1R3 receptor or fragments or sub-units thereof. The present invention also relates to the use of hetero-oligomeric and chimeric taste receptors comprising T1R1/T1R3 and T1R2/T1R3 in assays to identify compounds that respectively respond to umami taste stimuli and sweet taste stimuli. Further, the invention relates to the constitutive of cell lines that stably or transiently co-express a combination of T1R1 and T1R3; or T1R2 and T1R3; under constitutive or inducible conditions. The use of these cells lines in cell-based assays to identify umami and sweet taste modulatory compounds is also provided, particularly high throughput screening assays that detect receptor activity by use of fluorometric imaging.

公开(公告)号：US09783507B2

公开(公告)日：2017-10-10

申请号：US15419217

申请日：2017-01-30

申请人： THERAVANCE BIOPHARMA R&D IP, LLC

发明人： Melissa Fleury ,  Anne-Marie Beausoliel ,  Adam D. Hughes ,  Daniel D. Long ,  Donna A. A. Wilton

IPC分类号： C07D295/24 ,  C07D205/04 ,  C07D267/02 ,  C07D317/10 ,  C07D249/04 ,  C07D249/10 ,  C07D231/14 ,  C07D261/18 ,  C07D263/34 ,  C07D263/38 ,  C07D271/07 ,  C07D213/81 ,  C07D239/28 ,  C07D231/20 ,  C07D275/03 ,  C07D471/04 ,  C07D403/12

CPC分类号： C07D249/04 ,  A61K31/415 ,  A61K31/4192 ,  A61K31/4196 ,  A61K31/42 ,  A61K31/421 ,  A61K31/4245 ,  A61K31/425 ,  A61K31/437 ,  A61K31/44 ,  A61K31/4985 ,  A61K31/505 ,  A61K45/06 ,  A61P9/04 ,  A61P9/12 ,  A61P13/12 ,  C07C229/34 ,  C07C271/22 ,  C07D213/81 ,  C07D231/14 ,  C07D231/18 ,  C07D231/20 ,  C07D233/70 ,  C07D233/90 ,  C07D235/08 ,  C07D237/14 ,  C07D239/28 ,  C07D239/34 ,  C07D249/10 ,  C07D249/12 ,  C07D249/18 ,  C07D261/12 ,  C07D261/18 ,  C07D263/18 ,  C07D263/34 ,  C07D263/38 ,  C07D271/07 ,  C07D275/03 ,  C07D295/10 ,  C07D309/40 ,  C07D319/06 ,  C07D401/04 ,  C07D403/04 ,  C07D403/06 ,  C07D403/12 ,  C07D405/12 ,  C07D405/14 ,  C07D471/04

摘要： In one aspect, the invention relates to compounds having the formula I: where R1-R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.